Seminars in Diagnostic Pathology
Volume 25, Issue 3 , Pages 166-177 , August 2008

Hematopathology: a leap forward in pathology. A personal view

  • Jerónimo Forteza Vila

      Affiliations

    • Corresponding Author InformationAddress for correspondence: Jerónimo Forteza Vila, Departamento de Patología, Hospital Clínico Universitario Complejo Hospitalario y Universitario de Santiago, Choupana s/n Vidán, 15706 Santiago de Compostela, Spain

References 

  1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans. 1832;17:69–97
  2. Wilks S. Cases of enlargement of the lymphatic glands and spleen (or Hodgkin's disease), with remarks. Guys Hosp Rep. 1865;11:56–67
  3. Dawson PJ. The original illustrations of Hodgkin's disease. Arch Intern Med. 1968;121:288–290
  4. Fox X. Remarks on microscopical preparations mode from some of the original tissue described by Thomas Hodgkin, 1832. Ann Med Hist. 1926;8:370–374
  5. Sternberg C. Über eine eigenartige unter dem Bilde der Pseudoleukämie Verlaufende Tuberculose des lymphastischen Apparates. Ztschr Heilk. 1898;19:21–90
  6. Reed DM. On the pathological changes in Hodgkin′s disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10:133–196
  7. Dorfman RF, Gatter KC, Pulford KA, et al. An evaluation of the utility of anti-granulocyte and anti-leukocyte monoclonal antibodies in the diagnosis of Hodgkin's disease. Am J Pathol. 1986;123:508–519
  8. Mason DY, Gatter KC. The role of immunocytochemistry in diagnostic pathology. J Clin Pathol. 1987;40:1042–1054
  9. Bonadonna G. Historical review of Hodgkin's disease. Br J Hematol. 2000;110:504–511
  10. Gilbert R. La roentgenthérapie de la granulomatose maligne. J Radiol Electrol. 1925;9:509–514
  11. Goodman LS, Wintrobe MM, Dameshek W, et al. Nitrogen mustard therapy (Use of methylbis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, certain allied and miscellaneous disorders). J Am Med Assoc. 1946;132:126–132
  12. Kaplan HS. The radical radiotherapy or regionally localized Hodgkin's disease. Radiology. 1962;78:553–561
  13. Kaplan HS, Rosenberg SA. The treatment of Hodgkin′s disease. Med Clin North Am. 1966;50:1591–1610
  14. Jackson HJ, Parker F. Hodgkin's Disease and Allied Disorders. New York, NY: Oxford University Press; 1947;
  15. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063–1083
  16. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoma neoplasms: a proposal from international lymphoma study group. Blood. 1994;84:1361–1392
  17. Lukes RJ. Hodgkin's disease (Prognosis and relationship of histologic features to clinical stage). J Am Med Assoc. 1964;190:914–915
  18. Jaffe ES, Harris N, Stein H, et al. World Health Organization Classification of Tumors (Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues). Lyon: IARC Press; 2001;
  19. Fraga M, Forteza J. Diagnosis of Hodgkin's disease: an update on histopathological and immunophenotypical features. Histol Histopathol. 2007;22:923–935
  20. Marafioti T, Hummel M, Anagnostopoulos I. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453–458
  21. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95:1443–1450
  22. Kundrat H. Uber lympho-sarkomatosis. Wien Klin Wochenschr. 1893;6:234–239
  23. Virchow R. Die Krankenhaften Geschwulste, in Dreissig Vorlesungen gehalten wahrend des Wintersemestes (1862-1863) an der Universitat zu Berlin. In: Berlin: A Hirschwald; 1863-1867;p. 728–738
  24. Oberling C. Les réticulosarcomes et les réticulo-endothélio-sarcomes de la moelle osseuse (sarcomes d′Ewing). Bull Assoc Franç. P. l′étude du cancer. 1928;17:259–296
  25. Ewing J. Endothelioma of lymph nodes. J Med Res. 1913;28:1-40.7
  26. Aschoff L. Das Reticulo-endotheliale System Ergebn. Inn Med Kunderheilk. 1924;26:1
  27. Metchnikoff E. Lectures on the Comparative Pathology of Inflammation. New York, NY: Dover Publications; 1968;
  28. Robb–Smith AH. Reticulosis and reticulosarcoma (A histological classification). J Pathol Bacteriol. 1938;47:457–481
  29. Virchow R. Weisses Blut (Neue Notizen aus dem Gebiet der Natu-fund Heilkunde). Floriep′s Neue Notizen. 1845;36:151
  30. Bennet JH. Two cases of disease and enlargement of the spleen in which death took place from the presence of purulent matter in the blood. Edinb Med Surg J. 1845;64:413–423
  31. Neumann E. Über die Bedeutung des Knockenmarks fur die Blutbildung, Ein Beitrag zur Entwicklungsgeschichte der Blutkörperchen. Arch Heilkunde. 1869;10:68–102
  32. Minot GR, Buckman TE, Isaacs R. Chronic myelogenous leukemia- age incidence, duration, and benefit derived from irradiation. J Am Med Assoc. 1924;82:1489–1494
  33. Gall EA, Mallory TB. Malignant lymphoma: a clinico-pathological survery of 618 cases. Am J Pathol. 1942;18:381–429
  34. Dorfman RF. Maude Abbot lecture (Hematopathology: a crescendo of scholarly activity). Mod Pathol. 1994;7:226–241
  35. Rappaport H, Winter WJ, Hicks EB. Follicular lymphoma (A re-evaluation of its position in the scheme of malignant lymphoma based on a survey of 253 cases). Cancer. 1956;9:792
  36. Bulger R. Das grossfollikuläre Lymphoblastom: (die Brill-Symmerssche Krankheit). Ergebn D inn Med u Kinderh. 1954;5:642–706
  37. Brill NF, Baehr G, Rosenthal N. Generalized giant lymph node hyperplasia of lymph nodes and spleen (A hitherto undescribed type). J Am Med Assoc. 1925;84:668–671
  38. Symmers D. Follicular lymphadenopathy with splenomegaly (A newly recognized disease of the lymphatic system). Arch Pathol Lab Med. 1927;3:816–820
  39. Lennert K. Classification of malignant lymphoma. (European concept) In:  Rüttimann A editors. Progress in Lymphology. Stuttgart: Thieme; 1967;p. 103–109
  40. Dorfman RF. Present concepts of the proliferative and malignant diseases of the lymphoreticular tissues. Leech. 1961;31:10–16
  41. Rappaport H. Tumors of the Hematopoietic System (Atlas of Tumor Pathology). Washington DC: Armed Forces Institute of Pathology; 1966;
  42. Gall EA, Rappaport H. In:  McDonald JR editors. Proceedings of Seminar on Diseases of Lymph Node and Spleen. Chicago, IL: ASCP Press; 1958;
  43. De Vita VT, Rappaport H, Frei E. Announcement of formation of the lymphoma task force and pathology reference center. Cancer. 1968;22:1087–1088
  44. Greaves MF. Biological effects of anti-immunoglobulins: evidence for immunoglobulin receptors on T and B lymphocytes. Transplant. 1970;5:45–75
  45. Gérard–Marchant R, Hamlin I, Lennert K, et al. Classification of non-Hodgkin's Lymphomas (letter to the editor). Lancet. 1974;ii:406–440
  46. Lennert K. Pathologisch-anatomische klassification der malignen lymphome. Strahlentherapie (Sonderbd). 1969;69:1–7
  47. Lennert K, Mohri N, Stein H, et al. Malignant Lymphomas Other Than Hodgkin's Disease. Berlin: Springer; 1978;
  48. Lennert K, Feller AC. Histopathology of Non-Hodgkin's Lymphomas. New York, NY: Springer-Verlag; 1992;
  49. Lukes RJ, Collins RD. A functional approach to the classification of malignant lymphoma. Recent Results Cancer Res. 1974;46:18–30
  50. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer. 1974;34:1488–1503
  51. Lukes RJ, Collins RD. New approaches to the classification of the lymphomata. Br J Cancer. 1975;31:1–28
  52. Krueger G, Rojo J, Klein H, et al. A new working formulation of non-Hodgkin′s lymphomas: a retrospective study of the new NCI classification proposal in comparison to the Rappaport and Kiel classifications. Cancer. 1983;52:833–840
  53. Ersboll J, Schultz HB, Hougaard P, et al. Comparison of the Working Formulation of non-Hodgkin′s lymphoma with the Rappaport. Kiel, and Lukes & Collins classifications: translational value and prognostic significance based on review of 658 patients treated at a single institution. Cancer. 1985;55:2442–2458
  54. Lennert K. History of the European Association for Haematopathology. New York, NY: Springer; 2006;
  55. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting -Airlie House (Virginia, November, 1997). J Clin Oncol. 1999;17:3835–3849
  56. In:  Swerdlow SH,  Campo E,  Harris NL editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008;
  57. Burkitt D. A sarcoma involving the jaws of African children. Br J Surg. 1958;46:218–223
  58. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt′s lymphoma. Lancet. 1964;1:702–703
  59. Wright DH. What is Burkitt′s lymphoma and when is it endemic?. Blood. 1999;93:758–759
  60. Isaacson P, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology. 1987;11:445–462
  61. Isaacson P. Mucosa-associated lymphoid tissue lymphoma. Semin Hematol. 1999;36:139–147
  62. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–1493
  63. Perez–Rosado A, Artiga M, Vargiu P, et al. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas. J Pathol. 2008;214:498–507
  64. Alvaro T, Lejeune M, Salvadó MT, et al. Outcome in Hodgkin's Lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1473–1476
  65. Montalbán C, García JF, Abraira V, et al. Spanish Hodgkin's lymphoma study group Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's lymphoma study group. J Clin Oncol. 2004;22:1664–1673
  66. García JF, Camacho FI, Morente M, et al. Spanish Hodgkin lymphoma study group Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101:681–689
  67. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;[Epub ahead of print]
  68. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for the new targeted therapeutics. Nat Rev Cancer. 2007;7:750–762
  69. Salaverria I, Perez–Galan P, Colomer D, et al. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica. 2006;91:11–16
  70. Rosai J. Guiding the Surgeon's Hand (The History of American Surgical Pathology). Washington DC: American Registry of Pathology; 1997;
  71. Rosai J, Ackerman LV. Obituary. Am J Surg Pathol. 1994;18:211–213
  72. Ackerman LV. Surgical Pathology. St. Louis, MO: CV Mosby Company; 1968;
  73. Rosai J. Rosai and Ackerman's Surgical Pathology. (ed 9). New York, NY: Mosby; 2004;
  74. Mason D, Biberfeld P. Technical aspects of lymphoma immunohistology. J Histochem Cytochem. 1980;28:731–745
  75. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specifity. Nature. 1975;256:495–497
  76. Leong A, Wright J. The contribution of immunohistochemical staining in tumour diagnosis. Histopathology. 1987;11:1295–1305
  77. Miettinen M. Immunohistochemistry in tumour diagnosis. Ann Med. 1993;25:221–233
  78. Elias JM. Immunohistochemistry: a natural revolution. J Histotechnol. 1999;22:157–158
  79. Elias JM. Immunohistochemistry: a brief historical perspective. J Histotechnol. 1999;22:163–167
  80. Cartum R. Immunohistochemistry: 25 years and still going strong!. J Histotechnol. 2002;25:181–184
  81. Titford M. Review of an immunohistochemistry educational peer review program. J Histotechnol. 2002;25:259–261
  82. Mason DY. Innovations in immunohistochemistry for the haematopathologist. Ann Pathol. 2007;27:IS33–IS36
  83. Falini B, Solas I, Halverson C, et al. Double labeled-antigen method for demonstration of intracellular antigens in paraffin-embedded tissues. J Histochem Cytochem. 1982;30:21–26
  84. Chu PG, Chan JK, Arber DA, et al. Practical applications of immunohistochemistry in hematolymphoid neoplasms. Ann Diagn Pathol. 1999;3:104–133
  85. Chan JK. Mediastinal large B-cell lymphoma: new evidence in support of its distinctive identity. Adv Anat Pathol. 2000;7:201–209
  86. Chan JK. Anaplastic large cell lymphoma: redefining its morphologic spectrum and importance of recognition of the ALK-positive subset. Adv Anat Pathol. 1998;5:281–313
  87. Lejeune J. Leucémies et cancers. In:  Turpin R,  Lejeune J editor. Les Chromosomes Humains. Paris: Gauthier-Villars Press; 1965;
  88. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukaemia. Science. 1960;132:1497
  89. Baikie AG, Court–Brown WM, Buckton KE, et al. A possible specific chromosome abnormality in human chronic myeloid leukemia. Nature. 1960;188:1165–1166
  90. Baikie AG, Jacobs PA, McBride JA, et al. Cytogenetic studies in acute leukaemia. Br Med J. 1961;1:1564–1571
  91. Forteza–Bover G. Atlas of Blood Cytology (Cytomorphology, Cytochemistry and Cytogenetics). New York, NY: Grune & Stratton; 1964;
  92. Forteza–Bover G, Forteza–Vila J, Baguena CR, et al. Ultrastructures of human acute leukemia cells. Sangre. 1967;12:121–157
  93. Rwylin AM. Histopathology of the Bone Marrow. Boston, MA: Little, Brown and Company; 1976;
  94. Ventura RA, Martin–Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006;8:141–151
  95. Mattsson G, Tan SY, Ferguson DJP, et al. Detection of genetic alterations by immunoFISHanalysis of whole cells extracted from routine biopsy material. J Mol Diagn. 2007;9:479–489
  96. Downing JR, Shurtleff SA, Zielenska M, et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood. 1995;85:3416–3422
  97. llou L. Contribution of molecular biology and markers to the prognosis and management of patients with soft tissue sarcoma. Pathol Case Rev. 2008;13:69–77
  98. Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110:2–11
  99. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210BCR/ABL gene of the Philadelphia chromosome. Science. 1990;247:824–830
  100. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  101. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008;77:311–319
  102. Goldman JM, Melo JM. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1084–1086
  103. Schrödinger E. What is Life?. Cambridge: Cambridge University Press; 1944;
  104. Watson JD, Crick FHC. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature. 1953;171:737–738
  105. Collins F. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921
  106. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304–1351
  107. Achille A, Scarpa A, Montresor M, et al. Routine Application of polymerase chain reaction in the diagnosis of monoclonality of b-cell lymphoid proliferations. Diagn Mol Pathol. 1995;4:14–24
  108. Diss TC, Watts M, Pan X, et al. The polymerase chain reaction in the demonstration of monoclonality in t cell lymphomas. J Clin Pathol. 1995;48:1045–1050
  109. Medeiros LJ, Carr J. Overview of the Role of molecular methods in the diagnosis of malignant lymphomas. Arch Pathol Lab Med. 1999;123:1189–1207
  110. Lee C, Nielsen TO. Contribution of microarray analysis to soft tissue tumor diagnosis. Pathol Case Rev. 2008;13:78–84
  111. Martín–Subero JI, Gesk S, Harder L, et al. Interphase cytogenetics of hematological neoplasms under the perspective of the novel WHO classification. Anticancer Res. 2003;23:1139–1148
  112. Harris NL, Stein H, Coupland SE. New approaches to lymphoma diagnosis. Hematology Am Soc Hematol Educ Program. 2001;194–220
  113. Ladanyi M, Chan WC, Triche TJ, et al. Expression profiling of human tumours: the end of surgical pathology?. J Mol Diagn. 2001;3:92–97

PII: S0740-2570(08)00064-6

doi: 10.1053/j.semdp.2008.07.010

Seminars in Diagnostic Pathology
Volume 25, Issue 3 , Pages 166-177 , August 2008

Article Tools

* Image Usage & Resolution